Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status

Yu-Tang Chin, Zong-Rong He, Chi-Long Chen, Hsiao-Ching Chu, Yih Ho, Po-Yu Su, Yu-Chen S H Yang, Kuan Wang, Ya-Jung Shih, Yi-Ru Chen, Jens Z Pedersen, Sandra Incerpi, André Wendindondé Nana, Heng-Yuan Tang, Hung-Yun Lin, Shaker A Mousa, Paul J Davis, Jacqueline Whang-Peng

研究成果: 雜誌貢獻文章同行評審

19 引文 斯高帕斯(Scopus)


Colorectal cancer is a serious medical problem in Taiwan. New, effective therapeutic approaches are needed. The selection of promising anticancer drugs and the transition from pre-clinical investigations to clinical trials are often challenging. The deaminated thyroid hormone analog (tetraiodothyroacetic acid, tetrac) and its nanoparticulate analog (NDAT) have been shown to have anti-proliferative activity in vitro and in xenograft model of different neoplasms, including colorectal cancers. However, mechanisms involved in tetrac- and NDAT-induced antiproliferation in colorectal cancers are incompletely understood. We have investigated possible mechanisms of tetrac and NDAT action in colorectal cancer cells, using a perfusion bellows cell culture system that allows efficient, large-scale screening for mechanisms of drug actions on tumor cells. Although integrin αvβ3 in K-RAS wild type colorectal cancer HT-29 cells was far less than that in K-RAS mutant HCT116 cells, HT-29 was more sensitive to both tetrac and NDAT. Results also indicate that both tetrac and NDAT bind to tumor cell surface integrin αvβ3, and the agents may have different mechanisms of antiproliferation in colorectal cancer cells. K-RAS status appears to play an important role in drug resistance that may be encountered in treatment with this drug combination.

頁(從 - 到)130
期刊Frontiers in Endocrinology
出版狀態已發佈 - 1月 1 2019

ASJC Scopus subject areas

  • 內分泌學、糖尿病和代謝


深入研究「Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different K-RAS Status」主題。共同形成了獨特的指紋。